Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

摘要: Importance Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs their possible correlation with treatment response. Objective To describe frequency spectrum of AEs linked pembrolizumab Design, Setting, Participants A single-institution, retrospective medical record review was conducted cancer who were treated from March 1, 2011, to May 28, 2014. The comprised 83 consecutive enrolled 2 clinical received at least 1 dose had follow-up visit. Patients grouped according following therapeutic regimen for pembrolizumab: 43 10 mg/kg every 3 weeks, 24 16 weeks. Sixty-six melanoma, 15 lung cancer, patient prostate Merkel cell carcinoma. Median weeks (range, 2-105 weeks). analysis September 30, Main Outcomes Measures Occurrence, severity, type AEs, well disease progression response treatment. Results Thirty-five (42%) developed attributed pembrolizumab. most common macular papular eruption (24 [29%]), pruritus (10 [12%]), hypopigmentation (7 [8%]). All 7 melanoma. Survival analyses showed that significantly longer progression-free intervals all groups (pembrolizumab, mg/kg, weeks,P = .001; weeks,P = .003; weeks,P = .009) compared did not develop AEs. Conclusions Relevance Pembrolizumab therapy associated 42% patients. development especially could point toward better